Learn More
3032 Background: MGCD265 targets wild type Met, as well as clinically relevant Met mutants, VEGFR-1,-2 and -3, Ron and Tie-2. MGCD265 combinability with docetaxel has been evaluated in patients (pts)(More)
  • 1